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Mitochondrial turnoverMitochondria are intracellular power plants that feed most eukaryotic cells with the ATP produced by the
oxidative phosphorylation (OXPHOS). Mitochondrial energy production is controlled by many regulatory
mechanisms. The control of mitochondrial mass through both mitochondrial biogenesis and degradation has
been proposed to be one of the most important regulatory mechanisms. Recently, autophagic degradation of
mitochondria has emerged as an important mechanism involved in the regulation of mitochondrial quantity
and quality. In this review, we highlight the intricate connections between mitochondrial energy metabolism
and mitochondrial autophagic degradation by showing the importance of mitochondrial bioenergetics in this
process and illustrating the role of mitophagy in mitochondrial patho-physiology. Furthermore, we discuss
how energy metabolism could coordinate the biogenesis and degradation of this organelle. This article is part
of a Special Issue entitled: Mitophagy.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria produce energy through a complex interconnected
metabolic network using multiple energy sources, such as amino
acids, lipids and carbohydrate derivatives. This energy is produced in
the form of ATP and is delivered to all cellular compartments to feed
various cellular activities. Mitochondrial energy metabolism is highly
regulated to constantly meet the energetic needs of the cell and to uti-
lize the available energy substrates [1]. Among the multiple regulatory
processes involved, the control of mitochondrial mass is a crucial deter-
minant of the energymetabolism. In the steady state, themitochondrial
mass is determined by the balance of biogenesis and degradation.While
mitochondrial biogenesis has been intensively studied [2], the implica-
tions of mitochondrial degradation in the control of mitochondrial
mass have been a broadly uncharted area until recently. A pioneering
in vivo study conducted in 1971 demonstrated that the mitochondrial
network was dynamically renewed at different rates according to the
type of tissue [3]. The authors of this study postulated the existence
of degradation mechanisms aiming to “prevent accumulation of large
quantities of materials” [3]. Despite these early observations, the molec-
ular mechanisms of mitochondrial degradation and its physiologicalgy.
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).relevance and regulation remained unclear for several decades. In
2000, one of the ﬁrst characterizations of a speciﬁc and global mito-
chondrial degradation mechanismwas reported in mammalian embry-
os. This mechanism partially explained the elimination of paternal
mitochondria from the fertilized egg [4,5]. Later, two different groups
demonstrated the existence of a selective mitochondrial degradation
mechanism in yeast and somatic mammalian cells. The authors de-
scribed this degradation mechanism as a form of macroautophagy that
selectively eliminated mitochondria [6,7]; this degradation process has
been designated mitophagy [7]. Mitophagy consists of the hydrolytic
degradation of mitochondrial macromolecules, including lipids,
proteins and DNA, after their sequestration by a double-membrane
structure known as an autophagosome. This degradation mechanism
requires that the phagophore recognize, tether, and engulf the mito-
chondrion to form the autophagosome, followed by fusion of the
autophagosome with the lysosome [8]. Various autophagy-related pro-
teins (ATG) are required to form and regulate the autophagosome, and
speciﬁcmitochondrial proteins are necessary to recognize andmark the
mitochondria for mitophagy.
Recently, the importance of mitophagy has been revealed in multi-
ple physiological contexts, including the maturation of reticulocytes
[9,10], the inﬂammatory response initiated by NLRP3 [11] and the
reprogramming of T lymphocyte metabolism after antigen activation
[12]. Speciﬁcally, mitophagy appears to be a crucial mechanism for
mitochondrial quality control [13]. This mechanism has also been
associated with diseases such as type 1 diabetes and neurodegenerative
and mitochondrial disorders [14–16]. The link between mitophagy and
mitochondrial energy metabolism has been less well studied. However,
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between these processes. In the present review, we discuss recent ﬁnd-
ings showing the mutual interaction between mitochondrial energy
metabolism and mitophagy in physiological and pathological contexts.
We also illustrate how mitochondrial degradation and biogenesis
could be coordinated in terms of the energetic status of the cell.
2. Mitochondrial energy metabolism and mitophagy
In this section, wewill discuss the link betweenmitochondrial ener-
gy metabolism and the three main mitophagic mechanisms elucidated
to date [17].
2.1. Mitochondrial autophagic degradation in yeast
The ﬁrst speciﬁc mechanism of mitophagy was elucidated in yeast.
This mechanism involves components of the canonical autophagy
pathway but also includes very speciﬁc proteins that deﬁnemitophagy.
Indeed, mitophagy in yeast requires Atg32, an outer mitochondrial
membrane protein. This protein binds to Atg8, which is present at the
surface of the phagophore, through its WXXL domain [18,19]. By
interacting with Atg32 and the mitochondrial ﬁssion protein Dnm1,
the scaffold protein Atg11 also participates in the recruitment of
mitochondria for degradation [18,20]. These interactions stimulate the
expansion of the phagophore and the formation of the autophagosome
around themitochondria. Then, the autophagosome fuses with the vac-
uole, and the mitochondrion is degraded. Similarly to Atg32, Uth1 has
also been identiﬁed as an outer mitochondrial membrane receptor [6],
although its role may be linked to speciﬁc mitophagic signaling [21].
Numerous studies in yeast support a direct and mutual relationship
between mitophagy/autophagy and mitochondrial energy metabolism.
First, mitochondrial degradation through autophagic processes has
been observed after nutrient starvation and rapamycin treatment [6].
The speciﬁc energetic factor that signals mitochondrial degradation
through autophagic or mitophagic mechanisms under oxidative
conditions has not been clearly identiﬁed [22,23]. Defﬁeu et al. showed
that inhibition of the ubiquinone-cytochrome c oxidoreductase
(complex III) with antimycin A induced non-speciﬁc autophagy, but
not mitophagy [24]. However, the authors also observed that this acti-
vation of autophagy required the mitophagy-speciﬁc proteins Atg32
and Atg11 [24]. The same results were obtained using cyanide to inhibit
cytochrome c oxidase (COX). The use of another complex III inhibitor
(myxothiazol) had no effect on autophagy ormitophagy [24]. Unlike cy-
anide and antimycin A, myxothiazol did not enhance reactive oxygen
species (ROS) levels or the accumulation of the oxidized quinone.
Employing several ROS scavengers, these authors showed that nitrogen
starvation-induced mitophagy may not be linked to ROS damage but
rather to a decrease in the glutathione pool and a consequentmitochon-
drial redox imbalance [25]. Okamoto et al. showed that treatment with
the anti-oxidant N-acetyl-l-cysteine (NAC), which canmaintain or even
increase glutathione levels, reduced the expression of ATG32 under re-
spiratory growth conditions by half [18]. Thus, it appears thatmitochon-
drial redox signaling is sufﬁcient to regulatemitochondrial degradation.
It is still debatedwhether this degradation occurs through autophagy or
mitophagy. This questionmost likely relies on the timeline of events be-
cause it is demonstrated that mitophagy occurs after autophagic bulk
degradation [23].
Degradation through mitophagy in yeast can also be triggered
via the genetic impairment of oxidative phosphorylation (OXPHOS) ac-
tivity. Greaf et al. showed that defects in single or multiple respiratory
components in yeast were sufﬁcient to block ATG8 expression and the
autophagic ﬂux [26]. The authors demonstrated that the impairment
of the autophagic ﬂux was a consequence of ΔΨ collapse, whereas
mitochondrial ATP production appeared to have no impact [26]. Under
these conditions, the authors demonstrated that mitophagy wasdependent on protein kinase A (PKA) signaling. This PKA signaling can
regulate mitophagy as part of a general response to stressful
conditions [27].
These studies highlight the importance of mitophagy under stress
conditions in yeast and suggest that impairment of mitochondrial ener-
getic activity triggers mitophagy. This mechanism might help prevent
the accumulation of damages [28].
2.2. NIX-dependent mitophagy
Twomainmitophagymechanisms have been described in mamma-
lian cells to date. The ﬁrst mechanism occurs during reticulocyte matu-
ration. Reticulocytes are immature red blood cells that are devoid of
nuclei but contain organelles. During hematopoiesis, reticulocytes
must eliminate their highly abundant mitochondria to complete their
maturation into enucleated erythrocytes devoid of organelles. Mito-
chondria are eliminated from wild-type reticulocytes within 3 days,
and no mitochondria remain in the resulting erythrocytes. Mitophagic
clearance mobilizes the autophagic proteins ULK1 and ATG7 during
the early steps of this process [29]. Loss of autophagy in ATG7−/−mice
leads to defective removal of mitochondria from erythrocytes [30].
This process also involves the mitochondrial protein NIX (also known
as BNIP3L) [9,10]. In NIX-knockout reticulocytes, mitochondria are
retained in the enucleated cells [9,10]. NIX is a single-pass membrane
protein belonging to the BH3 family and is imbedded in the outer mito-
chondrial membrane. NIX contains an LC3-interacting region (LIR) cor-
responding to a WXXL motif in the N-terminal domain facing the
cytosol [31]. During mitophagy, NIX acts as the mitochondrial receptor
by recognizing the pool of LC3 present at the phagophore surface and
aids in the formation of the autophagosome around the mitochondria.
NIX-dependentmitophagy is closely linked to themitochondrial en-
ergetic status. Indeed, mitophagy in reticulocytes requiresmitochondri-
alΔΨ collapse. NIX-KO reticulocytes retain their mitochondrialΔΨ and
resist mitochondrial elimination unless the cells are treated with FCCP
[10]. NIX-dependent mitophagy is also linked to mitochondrial oxygen
metabolism [32]. Under hypoxic conditions, NIX and BNIP3, another
BH3 family protein and partner of NIX, are induced in a HIF1α-
dependent manner, and this induction leads to mitochondrial degrada-
tion [33,34]. Interestingly, hypoxia-induced hormones control the
expression of miRNAs (microRNAs) to speciﬁcally regulate NIX-
dependentmitophagy during reticulocytematuration [35]. Importantly,
hypoxia also regulates NIX-dependent mitophagy in other tissues. Both
brain tissues from mice and cell lines placed under hypoxic conditions
exhibit decreased expression of miR-137. MiR-137 speciﬁcally targets
NIX and FUNDC1, and repression of this miRNA promotes mitophagy
in these tissues [36]. Similar to NIX, FUNDC1 is amitochondrial receptor
that induces mitophagy and is regulated by hypoxia [37]. FUNDC1 also
contains an LIR domain and is embedded in the OMM through
three transmembrane domains, and silencing of FUNDC1 attenuates
hypoxia-induced mitophagy [37]. Re-expression of NIX and FUNDC1
without miR-137 binding sequences restores mitophagy by blocking
miRNA137-mediated suppression of NIX and FUNDC1. Interestingly,
hypoxia has been proposed to induce dephosphorylation of FUNDC1
and thereby enhance its interactionwith LC3 [37]. This regulation is un-
known for NIX to date.
Because NIX is expressed in various tissues and cell types [38], it
might be expected that NIX-dependent mitophagy is also important in
other contexts, similar to the participation of BNIP3 in mitophagy in he-
patic and cardiac muscle cells [38,39]. Recently, Melser et al. showed
that promotion of OXPHOS activity also induced NIX-dependent
mitophagy, regulated by the small GTPaseRHEB (RasHomolog Enriched
in Brain). Under high OXPHOS activity conditions, the interaction of
RHEB with NIX and LC3 to promote mitophagy appeared to prevent ox-
idative damage inmyoblasts [40]. Li et al. showed that RHEB could inter-
act with BNIP3 as well [41]. The effect of the RHEB/NIX interaction was
independent of mTOR [40], but RHEB/BNIP3 inhibited mTOR under
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by highmitochondrial ATP production and an increase in the rate of ox-
ygen consumption. Therefore, it is possible that the increase in oxygen
consumption might induce a localized hypoxia-like response that
promotes mitophagy, controlled by NIX and RHEB [40]. Notably, RHEB
is also regulated by miRNA induced by hypoxia [42].
Taken together, these ﬁndings show that NIX-dependent mitophagy
is not only central to reticulocyte maturation, but this process is also
important in hypoxia-related physiological responses in different
tissues (Fig. 1).2.3. PINK1/PARKIN-dependent mitophagy
One of themost signiﬁcant recent breakthroughs contributing to the
understanding of mitophagy was the ﬁnding that ΔΨ collapse leads to
mitophagy [43], and the involvement of the Parkinson's disease-
related proteins PINK1 and PARKIN in thismechanism [44]. PINK1 local-
izes to the mitochondrial outer membrane, but its abundance is low
under normal conditions due to rapid degradation. After depolarization
of the mitochondrial ΔΨ with CCCP, PINK1 degradation is slowed,
allowing the protein to build up in the outer membrane [45]. PINK1
kinase activity recruits PARKIN to the mitochondria [44,45]. Once at
the mitochondrion, PARKIN-mediated ubiquitination of mitochondrial
substrates, including VDAC1 and mitofusins (MFN1/2), leads to the re-
cruitment of p62/SQSTRM and LC3 [46–48]. Then, the mitochondrion
is engulfed into the autophagosome and eliminated throughmitophagy.
PINK1/PARKIN-dependent mitophagy is a quality control response
(Fig. 1). In cultured cells, PARKIN is speciﬁcally recruited to mitochon-
dria with a collapsedΔΨ [44]. This recruitment leads to the degradation
of damaged mitochondria and selectively maintains a healthy mito-
chondrial network [16]. PARKIN is highly expressed in tissues withFig. 1. Diagram of the links among the various mitophagy-related proteins. Interactions were p
relationships with various physiological processes.highmitochondrial activity, such as the brain, heart and skeletal muscle
[49,50]. In these tissues, the rate of mitochondrial bulk renewal is very
slow, as illustrated by reported half-lives of 23 and 18 days [3]. There-
fore, these tissues require speciﬁc mitochondrial quality control and it
seems that PINK1/PARKIN-dependent mitophagy plays this role.
PARKIN expression in the heart does not affect mitochondrial function
under basal conditions [51]. However, the expression of PARKIN in-
creases, and PARKIN-dependent mitophagy is stimulated after myocar-
dial infarction [51]. This response improves cardiac recovery [51]. In
contrast, in PARKIN-KOmice, failure to restore a normal cardiac pheno-
type is observed, and these animals display reduced survival after
cardiac infarction [51]. Additionally, PARKIN deﬁciency has been dem-
onstrated to induce heart defects in Drosophila due to the accumulation
of damaged mitochondria [52]. The role of PINK1/PARKIN-dependent
mitophagy in neurons is addressed speciﬁcally in Section 3.
Although the molecular mechanism has been conﬁrmed by many
different groups usingmultiple approaches, tools andmodels, the phys-
iological relevance of PINK1/PARKIN-induced mitophagy may not be
entirely clear [53–57]. As demonstrated for a variety of model cell
lines under glycolytic conditions, mitochondrial depolarization or
ROS-mediated damage robustly triggers the translocation of PARKIN
to mitochondria and the induction of mitophagy [44,58,59]. However,
there are other examples in which PARKIN is not strongly recruited to
mitochondria, and mitophagy is not induced following mitochondrial
depolarization [55,60]. Mitochondrial bioenergetic parameters, such as
the proton motive force, oxygen consumption and ATP production, are
different and are also regulated differentially according to the type of
cell or tissue. This might explain the discrepancies observed with
regards to PARKIN-dependent mitophagy. By comparing neurons and
myocytes, Yao et al. found that the loss of function associated with
PINK1 induced different responses in mitochondria depending on
the energy metabolism background [60]. The authors showed thatroposed using “String 9.05” online software. Human proteins are clustered to show their
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brane potential, whereas PINK1-deﬁcient neurons exhibited a de-
creased potential compared with their respective wild-type cells.
Interestingly, PINK1 deﬁciency induced impaired respiration in both
cell types [60]. The cell ability tomaintain or regulate these bioenergetic
parameters might reveal the physiological impact of PINK1/PARKIN-
induced mitophagy [60,61]. To date, PINK1/PARKIN-dependent
mitophagy has been mainly investigated in glycolytic cells using CCCP
to mimic mitochondrial damage [44]. From a bioenergetics point of
view, the use of uncouplers such as CCCP has three main effects:
(i) collapse of the proton motive force, (ii) a decrease in ATP synthesis
and (iii) an increase in oxygen consumption. It has not yet been clearly
established which parameter is important for stabilizing PINK1 and
recruiting PARKIN. Jin et al. demonstrated that PINK1 was stabilized at
the mitochondrial outer membrane after CCCP treatment but was de-
graded at the mitochondrial inner membrane [62]. Oligomycin treat-
ment promotes the stabilization of PINK1 in mitochondria. The use of
this drug, which blocks ATP production while the proton motive force
is retained, suggested the involvement of the proton motive force in
the regulation of PINK1 degradation [44,63]. However, these studies
have generally been performed under glycolytic conditions in which
mitochondrial ATP production (which is sensitive to oligomycin) repre-
sents only 5% of total ATP synthesis [40,64]. Themajority of ATP ismain-
tained through glycolysis. Thus, it is currently difﬁcult to estimate the
possible contribution of mitochondrial ATP production to the control
of mitophagy. PINK1/PARKIN-dependent mitophagy appears to be in-
duced at a lower level when studied under oxidative conditions [55].
Under these conditions, ATP is mainly produced by mitochondria, and
the use of CCCP collapses the potential but also induces dramatic ATP
depletion. This depletion negatively impacts physiological processes,
including PINK1/PARKIN-induced mitophagy. For example, ATP is a
crucial co-factor in protein import [65], and a decrease inmitochondrial
ATP after CCCP treatment could alter both the import of PINK1 and itsFig. 2. Illustration of the importance ofmitophagy in different physio-pathological situations. M
in fertilized eggs and during reticulocytematuration.Mitophagy is also involved in the control o
upon chronic and acute stimulation of mitochondrial energy metabolism (such as in the muscle
disease but also participates in the evolution of multiple diseases.degradation. PINK1 is a serine/threonine-protein kinase, and ATP levels
might be a crucial trigger for both kinase activity and regulation. Thus,
the lack of ATP might directly impede the catalytic activity of PINK1 or
affect its regulatory phosphorylation at Ser228 and Ser402, which are
critical for its kinase activity [66]. The studies performed in oxidative
condition suggest that PINK1/PARKIN-dependent mitophagy requires
bioenergetic co-factors. These co-factors are not yet fully identiﬁed
while their identiﬁcation might be essential to clarify the physiological
role of PINK/PARKIN-dependent mitophagy.
In summary, PINK1/PARKIN-dependent mitophagy represents a
mechanism for mitochondrial quality control in different tissues. This
mechanism relies on the balance between the mitochondrial energy
state (i.e., ATP, ROS, calcium buffering, and local hypoxia) and the level
of damage, rather than solely on the level of mitochondrial damage.
3. Mitochondrial degradation in pathological conditions
In this section, we will present some examples of pathological
situations in which mitophagy and mitochondrial energy metabolism
play or could play a crucial role (Fig. 2).
3.1. Neurological disorders
Mitochondrial dysfunction has been heavily implicated in
Parkinson's disease (PD) [67]. In particular, there is a speciﬁc decrease
in complex I activity and accumulation of deleted mitochondrial DNA
in the substantia nigra of PD patients [68,69]. Mutations in PARK6 and
PARK2, which encode the proteins PINK1 and PARKIN, respectively,
cause autosomal recessive PD. The defective clearance of damaged mi-
tochondria in the substantia nigra of PARK2 patients is expected to be
the crucial cause of the disease. However, this question is still heavily
debated due to the relatively low degree of mitophagy ormitochondrial
recruitment of PARKIN to the damaged mitochondria in neurons
[53–55,57]. Notably, Sterky et al. recently investigated mitochondrialitochondrial degradation participates in development by eliminating unwanted organelles
f mitochondrial contents in tissues in the resting state (such as in the pancreaticβ-cells) or
and liver). Impairment of mitochondrial degradation directly induces neurodegenerative
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cent reporter (mito-YFP) [56]. They used this reporter in the MitoPark
mice. The MitoPark mice display PD features due to speciﬁc knockout
of the mitochondrial transcription factor A (TFAM). Using these mice,
the authors showed that respiratory chain deﬁciency led to fragmenta-
tion of the mitochondrial network and the formation of large cytoplas-
mic bodies derived from mitochondria. Anterograde axonal transport
of mitochondria was also impaired in respiratory chain-deﬁcient DA
mouse neurons, leading to a decreased supply of mitochondria to the
axonal terminals. Interestingly, Sterky et al. showed that the dysfunc-
tional mitochondria did not recruit PARKIN in vivo, and neither the
clearance of defective mitochondria nor the neurodegeneration pheno-
type was affected by the absence of PARKIN in this model [56]. These
data suggest that mitochondrial dysfunction is not sufﬁcient to recruit
PARKIN and induce mitophagy. However, a recent study demonstrated
that PARKIN-dependentmitophagy occurred in distal axons in response
to local damage [58]. Thus, defects in mitochondrial clearance at crucial
neuronal regions could be sufﬁcient to induce neurodegeneration
through dying back mechanism [70].
Mutations in the presynaptic soluble protein α-synuclein cause an
autosomal dominant form of PD. Wild-type α-synuclein and its mutant
PD-causing form (A53T) both localize to mitochondria [71,72]. In the
mitochondria, α-synuclein can interact with complex I and under
normal conditions, low levels of mitochondrial α-synuclein have been
suggested to be necessary tomaintain OXPHOS integrity [71]. However,
the accumulation of wild-type α-synuclein or ectopic expression of the
α-synuclein A53Tmutant inducesmitochondrial dysfunction, including
impairment of complex I activity [71,72], in addition to promotingmito-
chondrial ﬁssion [73] and a dramatic increase in mitophagy [74,75]. In-
terestingly, mitophagy induced by the accumulation of α-synuclein
eliminates not only damaged mitochondria but also healthy mitochon-
dria with an intact ΔΨ [75]. Silencing of PARKIN or PINK1 impedes this
α-synuclein-induced mitophagy [75]. The ﬁnding that the accumula-
tion of α-synuclein causes major elimination of mitochondria and in-
creasingly impaired bioenergetics in PD suggests that hyperactive
mitophagy can induce neuronal cell death by diminishing the pool of
mitochondria necessary to sustain the energetic needs.
The role ofmitophagy in the course of other neurological disorders is
still controversial, but the interest in this topic is growing [76,77]. Many
studies have discussed the implications of mitophagy and PARKIN-
mediated mitophagy in neurodegenerative diseases, such as amyotro-
phic lateral sclerosis [78], Huntington's disease [79] mitochondrial dis-
ease [80], and Alzheimer's disease [81]. For example, recent ﬁndings
suggest a possible implication of mitophagy in the Down Syndrome
(DS). DS is a genetic disorder featuring neurological risks including
epileptic seizure and Alzheimer's disease. The Down Syndrome Critical
Region 1 gene (DSCR1), encoding calcipressin-1, shows elevated expres-
sion levels in the brains of patients with Down syndrome [82]. DSCR1 is
a soluble protein that is located in the mitochondrial intermembrane
space, and changes in its abundance affect mitochondrial activity,
mtDNA contents and mitochondrial size [83]. Chronic expression of
this protein in ST14A cells promotes mitophagy and inhibition of mito-
chondrial energy metabolism [84]. Additionally, the brains of patients
with Down syndrome exhibit an abnormal ROS balance and show in-
creased ROS accumulation [85], which are suggestive of damagedmito-
chondria. Further studies are required to clarify the precise role of
mitophagy in these diseases3.2. Diabetes
Mitochondrial degradation can be acutely promoted or inhibited by
hormones. For instance, thyroid hormones inhibit mitochondrial degra-
dation in the heart [86], whereas fasting and glucagon increase
mitochondrial degradation through mitophagy and non-selective au-
tophagy in hepatocytes [87,88]. Because these hormones control energy
homeostasis in the body and play important roles in various metabolicdisorders, there is growing interest in investigating mitophagy in the
context of obesity [89], type 1 diabetes [90] and type 2 diabetes [91,92].
Tumor protein p53-inducible nuclear proteins 1 and 2 (TP53INP1
and TP53INP2) have been previously reported to be susceptibility
genes for type 2 diabetes. These two proteins contain LIR domains and
may therefore play a role in autophagy [93]. Recently, mice lacking
TP53INP1 were shown to be prone to redox-driven obesity and insulin
resistance. TP53INP1-KO mice displayed mitophagy defects, leading to
an increase in damagedmitochondria [92]. This defectivemitophagy in-
duced a decrease in oxygen consumption rates and an increase in mito-
chondrial ROS production. Interestingly, TP53INP1 is also found in the
mitochondria and interacts with PINK1 and PARKIN, but not with NIX
and BNIP3 [92]. Like TP53INP1, TP53INP2 regulates autophagy and is re-
quired for autophagosome formation and processing [94], and
TP53INP2 expression is repressed in muscle tissues from patients with
type 2 diabetes and in murine models of diabetes [95]. The role of this
protein in mitophagy is still to be determined.
In the basal state, autophagy is required for pancreatic β cell
function, and genetic inactivation of the autophagic machinery in
ATG7-knockout mice resulted in decreased glucose-stimulated insulin
secretion [96]. Interestingly, the type 1 diabetes susceptibility gene
CLEC16a [90] has been shown to regulate mitophagy in β cells [14]. Pa-
tients bearing a diabetes-inducing form of CLEC16A showed a reduction
in CLEC16A expression in islets and reduced insulin secretion. In mice,
speciﬁc loss of CLEC16a in β cells hampered mitophagy, leading to con-
secutive accumulation of defective mitochondria and an impairment of
mitochondrial OXPHOS [14]. Mitochondrial OXPHOS dysfunction in β
cells is known to strongly impair glucose oxidation and insulin secretion
[97–99]. Taken together, these studies suggest that basal mitochondrial
degradation in β cells contributes to the physiological regulation of in-
sulin secretion by controlling mitochondrial mass and mitochondrial
energy metabolism. Deregulation of this mechanism in β cells leads to
type1 diabetes.
3.3. DNA repair-associated disorders
Several independent and recent studies have associated DNA repair
pathologies with mitophagy and mitochondrial energetic function. Fei
Fang et al. proposed that several DNA repair syndromes, such as
xeroderma pigmentosum group A (XPA), Cockayne syndrome (CS)
and Ataxia-telangiectasia (AT), are similar to several mitochondrial dis-
eases [100]. Togetherwith analteration ofmitochondrial energetic func-
tion, these authors observed defective mitophagy in XPA patient
ﬁbroblasts [100]. Using XPA-deﬁcient cell models, they detected exces-
sive cleavage of PINK1 and an increased mitochondrial ΔΨ. Interesting-
ly, patientswith CS showed accumulation of damagedmitochondria due
to decreased autophagy [101]. It is noteworthy that DNA damage, telo-
mere shortening, oxidative damage and a compromised mitochondrial
energy metabolism were also observed in patients with accelerated
aging disorders, such as Werner syndrome [101,102].
AT is a neurodegenerative disorder associatedwith an increased risk
of cancer and immunodeﬁciency. This syndrome is characterized by se-
vere mitochondrial dysfunction. Cells from patients with AT display an
altered mitochondrial organization and increased mitochondrial con-
tent [103,104]. These patients' cells are in a continuous state of oxidative
stress, exhibiting a decreased ΔΨ and elevated expression of oxidative
stress response genes [104]. AT, also known as Louis–Bar Syndrome, is
caused by an autosomal recessive mutation in the ATM gene, which en-
codes a 370 KDa Ser/Thr kinase involved in DNA repair and genotoxic
stress. Valentin-Vega et al. demonstrated that thymocytes from Atm-
null mice showed an abnormal mitochondrial morphology and deﬁ-
ciencies in mitochondrial electron transport chain activity, which were
correlated with reduced ATP levels and elevated mitochondrial ROS
contents [105]. Although ATM is mostly nuclear, this protein can also
translocate to the mitochondria. ATM is activated by a collapse of the
mitochondrial ΔΨ and plays a role in mitophagy, as demonstrated by
the accumulation of damaged mitochondria in response to the loss of
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due to the loss of hypoxia sensing [106].
3.4. Lipid metabolism-associated disorders and lysosomal storage disorders
Maintenance of the mitochondrial membrane lipid composition is
critical for determiningmitochondrial shape and function.Mitochondri-
al dysfunctions resulting from the deregulation of fatty acid synthesis
contribute to several diseases [107]. Phosphatidic acid (PA), a fusogenic
phospholipid located at the mitochondrial surface, and mitochondria-
localized phospholipase D (MitoPLD), can dramatically inﬂuence mito-
chondrial fusion/ﬁssion. MitoPLD uses cardiolipin as a substrate to
generate PA [108]. Cardiolipins are present exclusively in themitochon-
dria, where they provide structure to membranes and functional
support to the enzymes involved in bioenergetics [109]. Recently,
cardiolipin was shown to be externalized to the mitochondrial outer
membrane in neuronal cells, where it served as a mitophagic receptor
and interacted with LC3 after mitophagic stress [110]. Defects in
cardiolipin synthesis and translocation at the OMM reduced mitophagy
[110]. Cardiolipin remodeling involves the membrane protein Tafazzin.
Tafazzin gene (TAZ)-associated mutations induce a reduction in
cardiolipin synthesis and are responsible for a severe raremitochondrial
disorder referred to as Barth syndrome (BS). BS is a multisystemic pa-
thology characterized by cardiomyopathy, metabolic impairment, neu-
tropenia and growth retardation [111]. Patients with Barth syndrome
exhibit altered OXPHOS activity and overall mitochondrial abnormali-
ties [112]. Although the manifestations of Barth syndrome have not
been clearly demonstrated to be a consequence of inhibited mitophagy,
mitochondrial damage and abnormal mitophagy are observed in the
skeletal muscle of both TAZ-knockdown mice and Barth syndrome
patients [113]. Additionally, oxidative stress and diet-induced obesity
enhance the expression of the mitochondrial lysocardiolipin acyltrans-
ferase, ALCAT1. ACALT1 overexpression produces abnormal remodeling
of cardiolipin and defective mitophagy [114]. This defective mitophagy
induces oxidative stress that can lead to obesity [115] and liver steatosis
[114]. Interestingly, deletion of ALCAT1 prevented defective mitophagy
in a model of hyperthyroid cardiomyopathy [114,116].
Lysosomal storage diseases (LSDs) are a group of rare inheritedmet-
abolic disorders caused by a deﬁciency in lysosomal functions, including
defects in lysosomal enzymes or nonenzymatic lysosomal proteins. Im-
pairment of lysosomal function in LSDs is mainly characterized by de-
fective elimination of lipids, proteins and organelle aggregates [117].
Interestingly, accumulation of mitochondria with an altered morpholo-
gy and deﬁcient energetic activity are observed in various LSDs
[118–120]. Approximately two-thirds of LSDs involve the central ner-
vous system and present neurodegenerative features [121]. Speciﬁcally,
mutations in the glucocerebrosidase gene (GBA) leading to Gaucher dis-
ease represent a risk factor for developing Parkinson's disease [122]. A
mousemodel of Gaucher disease carryingGBAmutationspresented var-
ious markers of neurodegeneration, including the accumulation of α-
synuclein, ubiquitinated proteins and altered mitochondria [120]. Fur-
thermore, GBA activity is signiﬁcantly decreased in the substantia nigra
of sporadic Parkinson's patients [123]. Pablo-Latorre et al. showed that
embryonic cells from a mouse model of Multiple Sulfatase Deﬁciency
(MSD) failed to recruit PARKIN to mitochondria under CCCP treatment,
and the mitochondria consequently failed engulfment into the
autophagosomes [124]. These ﬁndings suggest that a lack of mitochon-
drial quality control can result in the accumulation of defective mito-
chondria observed in LSDs.
Although the molecular basis of mitophagy is not completely
established, it is clear that this process is involved in many different
diseases either as a mitochondrial quality or quantity control system.
4. Coordination with mitochondrial biogenesis
During the steady state, the number of mitochondria present
depends on the balance of mitochondrial biogenesis and degradationprocesses, which must be coordinated. The AMPK and mTORC1 signal-
ing pathways are two central energy sensors that can connect the regu-
lation of mitochondrial mass to (i) energy demands and expenditures
and (ii) substrate availability (Fig. 3).
4.1. mTORC1. Themammalian target of rapamycin complex 1 (mTORC1)
may be one of the central regulators of mitochondrial mass and turn-
over. ThemTORC1 signaling pathway plays a central role inmaintaining
the cellular homeostasis required to drive normal development and cell
growth. This complex iswell known because it integrates signals related
to energy status and nutrient availability (i.e., amino acids, glucose and
oxygen) to control cell growth [125]. The mTORC1 signaling pathway is
inhibited under conditions of limited nutrient availability and energetic
crises as well as after pharmacologic treatmentwith rapamycin; this in-
hibition promotes the degradation of proteins and organelles through
autophagic processes [125]. Inhibition of mTORC1 activity removes
the repression of a complex that includes ULK1, FIP200 and ATG13,
resulting in autophagy. Hypoxia also hampers mTORC1 signaling
through different pathways. One of these pathways requires the activa-
tion of the hypoxia-sensing protein REDD1, which localizes to themito-
chondria [126]. Mitochondrial degradation occurs during mTORC1-
dependent autophagy, but this is not a speciﬁc mitophagy mechanism
[127]. Interestingly, increases in mTORC1-dependent autophagy are
concomitant with the mitochondrial loss of energetic function. For in-
stance, knockdown of RAPTOR and disruption of mTORC1 decrease ox-
ygen consumption [127], and inhibition of mTORC1 with rapamycin
decreases the mitochondrial ΔΨ, oxygen consumption and cellular
ATP levels and profoundly alters the mitochondrial phosphoproteome
[127,128]. In parallel, mTORC1 directly controls the interaction between
the transcription factor YY1 and the nuclear co-factor PGC1-α, thereby
regulating mitochondrial protein expression [129]. This ﬁnding high-
lights the key role played by this complex in mitochondrial biogenesis
and oxidative metabolism [129]. Therefore, mTORC1 signaling is capa-
ble of integrating information concerning the availability of energetic
substrates (i.e., oxygen, amino acids or glucose) to coordinate the con-
trol of both mitochondrial degradation and biogenesis. This coordina-
tion can occur at the tissue level; indeed, tissues can transiently
promote either mitochondrial degradation or biogenesis, according to
their energy demands. This function is exempliﬁed in obesity and type
2 diabetes [130], which are conditions that are linked to elevated
mTORC1 activation [131] but are characterized by impaired mitochon-
drial biogenesis in muscles [132], increased OXPHOS levels in the liver
[133], and decreased OXPHOS in the heart [134].
4.2. AMPK. Another strong candidate for involvement in the coordina-
tion of mitophagy and mitochondrial biogenesis is the AMPK signaling
pathway. AMPK (AMP-activated protein kinase) is sensitive to the intra-
cellular ratio of AMP/ATP [135]. While the mTORC1 signaling pathways
integrate information concerning the nutrients available in the nearby
environment, the AMPK pathway senses the intracellular energy status.
AMPK activates energy-producing pathways and inhibits energy-
consuming processes when intracellular ATP levels are low, reﬂecting
an increased demand for energy [135]. Activation of AMPK signaling
through daily muscular training [136] or the use of pharmacological
treatments such as AICAR [137] increase the cellular and tissue mito-
chondria content. To sustain the intracellular mitochondrial energyme-
tabolism, AMPK can regulate both mitochondrial degradation and
biogenesis. Several studies have demonstrated that AMPK signaling
promotes mitochondrial biogenesis through direct phosphorylation of
PGC1α [138] or via a SIRT1-dependent indirect circuit [139]. Two recent
studies have shown that the activation of AMPK by glucose deprivation
and AICAR treatment promotes mitophagy through the direct phos-
phorylation of ULK1 [140,141]. As a result, AMPK stimulates both
mitophagy and mitochondrial biogenesis when energy levels are low.
The consequences of the concomitant activation of mitochondrial bio-
genesis and mitophagy are unclear in terms of the net balance of
Fig. 3. Coordination of mitochondrial degradation and biogenesis mediated by themTORC1- and AMPK-dependent signaling pathways under different conditions of substrate availability
(A) or under different states of energy demand (B).
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ses can be put forth. For instance, AMPK-dependent mitophagy may
ameliorate mitochondrial bioenergetics by preventing damage. In this
case, mitophagy is only weakly activated or functions at a slow rate,
and only damaged mitochondria are eliminated. This type of mecha-
nismhas been suggested for RHEB-dependentmitophagy [40]. A second
possibility is cell- or tissue-dependent AMPK signaling [142,143]. For in-
stance, inactivation of the AMPK pathway promotes mitophagy in oxi-
dative skeletal muscle, resulting in increased expression of PARKIN
and BNIP3, whereas its activation leads to the induction of PGC1α-
dependent biogenesis [144]. The coordination of these processes may
be different in other tissues (e.g., AMPKmight regulate only one speciﬁc
mitochondrial process). A third possibility may be that AMPK responses
merge with other mitochondrial biogenesis and mitophagy signaling
pathways (e.g., the mTORC1 pathway), as proposed by Kim et al. [141].
Finally, mTORC1 and AMPK control both mitochondrial biogenesis
and degradation. However, details regarding the coordination of these
processes are still lacking because they have mainly been investigated
separately.5. Conclusions
In this review, we highlighted the various links between mitochon-
drial energy metabolism and mitochondrial degradation. Speciﬁcally,
we illustrated how the different components of mitochondrial bioener-
getics (i.e., ΔΨ, ATP production, oxygen consumption and ROS) play
central roles in the regulation of mitophagy. By indicating the physio-
logical status of themitochondria, these factors contribute to the induc-
tion or inhibition of mitophagy. Currently, it is unclear whether one
parameter or a combination of parameters induces a speciﬁc type of
mitophagy. Therefore, to better understand the physiological relevance
of multiple types of mitophagy, it is important to decipher the bioener-
getic triggers and the resulting signaling pathways involved in these
mechanisms. In a reciprocalmanner, mitophagy regulatesmitochondri-
al energy metabolism by controlling the amount and the efﬁciency of
the mitochondrial metabolic machinery. The amount and efﬁciency of
mitochondria are also controlled by mitochondrial biogenesis, but the
coordination between mitochondrial biogenesis and mitophagy cur-
rently remains an unanswered question. These questions surrounding
2819S. Melser et al. / Biochimica et Biophysica Acta 1853 (2015) 2812–2821the coordination of mitochondria bioenergetics, dynamics and turnover
will hopefully provide future directions for the study of mitochondrial
energy metabolism and mitophagy.
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